Pasteur's country will (finally) be able to use its own vaccine against Covid-19.
The High Authority for Health (HAS) issued a favorable opinion on Thursday for the booster use of two new vaccines in adults, including VidPrevtyn, produced by Sanofi, in France.
The authority also expanded the use of the Novavax vaccine.
The available data "show favorable results in terms of immune response, as well as a tolerance of the vaccine comparable to that of other vaccines", reports the HAS.
These two serums are presented as "effective and useful to meet the needs of people reluctant to mRNA vaccines and those with a contraindication".
Read alsoCovid-19: should we be worried about the ninth wave?
Sanofi and Novavax have developed recombinant protein vaccines, which use the Spike protein of the virus as an antigen to help the body recognize it.
The French pharmaceutical giant Sanofi admitted last May that it had suffered a “failure” in the development of its anti-Covid serum, a niche in which it was clearly behind competitors like the American Pfizer.
Faced with the epidemic rebound, the HAS reaffirmed the importance of recall, the “best weapon to protect people at risk of a severe form of the disease.
“Since October 3, the most fragile are called upon to be vaccinated again in order to avoid a serious form of the disease.
The booster is six months after the last dose (three for those over 80) or three months after the infection.
The High Authority still insists on the need to reinforce respect for barrier gestures to reduce the transmission of the virus.
On the other hand, the Valneva vaccine is rejected as a primary vaccination as well as a booster, for lack of sufficiently numerous and solid data, indicates the HAS.